Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

The United States Pharmacopeial (USP) Convention signed a memorandum of understanding (MOU) with the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor) last week in Moscow.

USP Forms Collaboration with Russia

Also, Sanofi-aventis acquires Medley and Laboratorios Kendrick; Eli Lilly's Cook to retire from board; more...

Company and People Notes: DSM and Shire Form Pact; Pfizer Names Oncology Unit Exec; More...

Also, Genzyme and Bayer HealthCare form agreement; FDA releases draft guidances; TransMolecular appointed Robert Radie president and CEO

Company and People Notes: BMS and Otsuka Extend Abilify Agreement; Takeda Reorganizes Corporate Structure; More...

The financial crisis is adding further injury to already weakened prospects for the pharmaceutical industry.

A Sobering PharmaChem Outlook

Follow-on biologics or biosimilars offer a niche growth market for the pharmaceutical industry. As the process for establishing a regulatory pathway for biosimilars is debated, companies, including Big Pharma, are positioning themselves to gain this piece of the pharmaceutical pie.

Gauging Opportunities in the Biosimilars Market

The US Senate introduced a bipartisan bill (S. 726) on Mar. 26, 2009, which establishes a regulatory pathway for approval of biosimilars.

Senate Introduces Bipartisan Bill on Biosimilars

Also, SOCMA changes name; two FDA approvals; Biogen Idec names chief operating officer; more...

Company and People Notes: EMD Serono to Open Cambridge, MA, site; Akorn Appoints Interim CEO; More...

Michelle Hoffman, editorial director of Pharmaceutical Technology.

Obama's cost-containment and science-innovation initiatives need to overlap.

Parallel Tracks

A review of recent product innovations, policy developments, and growth prospects in the excipients market.

Tracking Excipients

The financial and economic downturn is likey to have long-term implications for outsourcing.

Ingredients